Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin

American Journal of Translational Research

Volumn 1, Issue 4, 2009, Pages 393-405

  Ling, Xiang ^a   He, Xiang ^a,b   Apontes, Pasha ^a   Cao, Felicia ^a   Azrak, Rami G ^a   Li, Fengzhi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Breast cancer cells; Irinotecan; Resveratrol; SN38; Survivin; T138067

Indexed keywords

2 FLUORO 1 METHOXY 4 PENTAFLUOROPHENYLSULFONAMIDOBENZENE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; PROTEIN KINASE B; RESVERATROL; SURVIVIN; T 138067; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

VITACEAE;

EID: 77449085174     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Altieri DC, Marchisio PC and Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 1999; 79: 1327-1333.
2. Li F. Survivin Study: What is the next wave? J Cell Physiol 2003; 197: 8-29.
3. Li F and Ling X. Survivin Study: An update of "What is the next wave?" J Cell Physiol 2006; 208: 476-486.
4. Grossman D and Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001; 20: 3-11.
5. Zaffaroni N, Pennati M and Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005; 9: 360-372.
6. Altieri DC. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 2006; 5: 478-482.
7. Ling X, Bernacki RJ, Brattain MG and Li F. Induction of survivin expression by taxol (paclitaxel) is an early event which is independent on taxol-mediated G2/M arrest. J Biol Chem 2004; 279: 15196-15203.
8. Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL, Shipley WU and Chakravarti A. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 2005; 64: 293-302.
9. Tirro E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A and Vigneri P. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 2006; 66: 4263-4272.
10. Tran J, Master Z, Yu JL, Rak J, Dumont DJ and Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 2002; 99: 4349-4354.
11. Wang L, Zhang GM and Feng ZH. Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60/ADR cell line. Acta Pharmacol Sin 2003; 24: 1235-1240.
12. Wu J, Ling X, Pan D, Apontes P, Song L, Liang P, Altieri DC, Beerman T and Li F. Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence selective DNA-binding antitumor agent, hedamycin: evidence of survivin downregulation associated with drug sensitivity. J Biol Chem 2005; 280: 9745-9751.
13. Wu J, Apontes P, Song L, Liang P, Yang L and Li F. Molecular mechanism of upregulation of survivin transcription by the AT-rich DNA-binding ligand, Hoechst33342: evidence for survivin involvement in drug resistance. Nucleic Acids Res 2007; 35: 2390-2402.
14. Sayeed A, Konduri SD, Liu W, Bansal S, Li F and Das GM. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res 2007; 67: 7746-7755.
15. Li F. Role of survivin in cancer chemoprevention. Assay Designs-Simply Science 2005; 1: 2-6.
16. Riles WL, Erickson J, Nayyar S, Atten MJ, Attar BM and Holian O. Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J Gastroenterol 2006; 12: 5628-5634.
17. Hu Y, Rahlfs S, Mersch-Sundermann V and Becker K. Resveratrol modulates mRNA transcripts of genes related to redox metabolism and cell proliferation in non-small-cell lung carcinoma cells. Biol Chem 2007; 388: 207-219.
18. Mallikarjuna G, Dhanalakshmi S, Singh RP, Agarwal C and Agarwal R. Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Res 2004; 64: 6349-6356.
19. Singh RP, Dhanalakshmi S, Agarwal C and Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 2005; 24 1188-1202.
20. Scheper MA, Sauk JJ and Nikitakis NG. COX-independent antineoplastic effects of sulindac in oral cancer are mediated by survivin down-regulation. Anticancer Res 2006; 26: 4103-4113.
21. Jin HO, Yoon SI, Seo SK, Lee HC, Woo SH, Yoo DH, Lee SJ, Choe TB, An S, Kwon TJ, Kim JI, Park MJ, Hong SI, Park IC and Rhee CH. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem Pharmacol 2006; 72: 1228-1236.
22. Azrak RG, Frank CL, Ling X, Slocum HK, Li F, Foster BA and Rustum YM. The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Mol Cancer Ther 2006; 5: 2540-2548.
23. Chun JY, Hu Y, Pinder E, Wu J, Li F and Gao AC. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther 2007; 6: 2572-2580.
24. Christine Pratt MA, Niu M and White D. Differential regulation of protein expression, growth and apoptosis by natural and synthetic retinoids. J Cell Biochem 2003; 90: 692-708.
25. Pratt MA, Niu MY and Renart LI. Regulation of survivin by retinoic acid and its role in paclitaxel-mediated cytotoxicity in MCF-7 breast cancer cells. Apoptosis 2006; 11: 589-605.
26. Li F, Ling X, Huang H, Brattain L, Apontes P, Wu J, Binderup L and Brattain MG. Differential regulation of survivin expression and apoptosis by vitamin D(3) compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 2005; 24: 1385-1395.
27. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005; 92: 212-216.
28. Miyachi K, Sasaki K, Onodera S, Taguchi T, Nagamachi M, Kaneko H and Sunagawa M. Correlation between survivin mRNA expression and lymph node metastasis in gastric cancer. Gastric Cancer 2003; 6: 217-224.
29. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH and Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006; 55: 1294-1298.
30. Marioni G, Bertolin A, Giacomelli L, Marchese-Ragona R, Savastano M, Calgaro N, Marino F, De Filippis C and Staffieri A. Expression of the apoptosis inhibitor protein Survivin in primary laryngeal carcinoma and cervical lymph node metastasis. Anticancer Res 2006; 26: 3813-3817.
31. Thomas J, Liu T, Cotter MA, Florell SR, Robinette K, Hanks AN and Grossman D. Melanocyte Expression of Survivin Promotes Development and Metastasis of UV-Induced Melanoma in HGF-Transgenic Mice. Cancer Res 2007; 67: 5172-5178.
32. Ouhtit A, Matrougui K, Bengrine A, Koochekpour S, Zerfaoui M and Yousief Z. Survivin is not only a death encounter but also a survival protein for invading tumor cells. Front Biosci 2007; 12: 1260-1270.
33. Shan B, Medina JC, Santha E, Frankmoelle WP, Chou TC, Learned RM, Narbut MR, Stott D, Wu P, Jaen JC, Rosen T, Timmermans PB and Beckmann H. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci U S A 1999; 96: 5686-5691.
34. Ling X and Li F. Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. BioTechniques 2004; 36: 450-454, 456-460.
35. Hayashibara T, Yamada Y, Nakayama S, Harasawa H, Tsuruda K, Sugahara K, Miyanishi T, Kamihira S, Tomonaga M and Maita T. Resveratrol Induces Downregulation in Survivin Expression and Apoptosis in HTLV-1-Infected Cell Lines: A Prospective Agent for Adult T Cell Leukemia Chemotherapy. Nutr Cancer 2002; 44: 193-201.
36. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I and Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398.
37. Schibler MJ and Cabral F. Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin. J Cell Biol 1986; 102: 1522-1531.
38. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T and Poruchynsky MS. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272: 17118-17125.
39. Shen D, Pastan I and Gottesman MM. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 1998; 58: 268-275.
40. Shen DW, Goldenberg S, Pastan I and Gottesman MM. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 2000; 183: 108-116.
41. Levenson VV, Davidovich IA and Roninson IB. Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response. Cancer Res 2000; 60: 5027-5030.
42. Jacob S, Aguado M, Fallik D and Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001; 61: 6555-6562.
43. Ikeguchi M, Liu J and Kaibara N. Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis 2002; 7: 23-29.
44. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F and Daidone MG. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002; 59: 1406-1412.
45. Asanuma K, Kobayashi D, Furuya D, Tsuji N, Yagihashi A and Watanabe N. A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res 2002; 93: 1057-1062.
46. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q and Loeffler J. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004; 23: 7494-7506.
47. Notarbartolo M, Cervello M, Dusonchet L, Cusimano A and D'Alessandro N. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett 2002; 180: 91-101.
48. Kirby S, Gertler SZ, Mason W, Watling C, Forsyth P, Aniagolu J, Stagg R, Wright M, Powers J and Eisenhauer EA. Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group. Neuro-oncol 2005; 7: 183-188.
49. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M and Sasamata M. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021.
50. Rubenstein SM, Baichwal V, Beckmann H, Clark DL, Frankmoelle W, Roche D, Santha E, Schwender S, Thoolen M, Ye Q and Jaen JC. Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem 2001; 44: 3599-3605.